2 recruiting, 1 active not recruiting. 3 Phase 2, 2 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Recruiting 2, Active not recruiting 1 |
| Phase 1 | 2 | Active not recruiting 1, Recruiting 1 |
Follow Opevesostat: new trials by email Literature Review of Opevesostat trials Research Report on Opevesostat
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of MK-5684 in People With Certain Solid Tumors (MK-5684-015/OMAHA-015) Opevesostat, Fludrocortisone/ Fludrocortisone acetate, Dexamethasone/Dexamethasone acetate - Malignant Neoplasm | Phase 2 | Recruiting | Merck Sharp & Dohme LLC | 250 | 2025-08-11 | 2026-10-06 |
| A Clinical Study of Ifinatamab Deruxtecan Based Treatment Combinations or as Monotherapy to Treat Metastatic Castrate Resistant Prostate Cancer (mCRPC) (MK-2400-01A/IDeate-Prostate02) Docetaxel, Ifinatamab Deruxtecan, Opevesostat - Castration-Resistant Prostatic Cancer, Metastasis | Phase 1 / Phase 2 | Recruiting | Merck Sharp & Dohme LLC | 360 | 2025-07-03 | 2026-10-09 |
| Substudy 01A: Safety and Efficacy of Opevesostat (MK-5684)-Based Treatment Combinations or Opevesostat Alone in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-5684-01A) Opevesostat, Olaparib, Docetaxel - Prostatic Neoplasms, Castration-Resistant | Phase 1 / Phase 2 | Active not recruiting | Merck Sharp & Dohme LLC | 220 | 2024-05-20 | 2026-10-29 |
Prostatic Neoplasms, Castration-Resistant (2) · Neoplasm Metastasis (1) · Neoplasms (1)
Canada (3) · Chile (3) · Spain (3) · Taiwan (3) · Turkey (Türkiye) (3) · United Kingdom (3) · United States (3) · Argentina (2) · Australia (2) · Brazil (2) · France (2) · Germany (2) · Ireland (2) · Israel (2) · Italy (2)
2023 (1)